Skip to content

Effect of taking Montelukast tablets in mouth ulcers

Effect of Montelukast in minor recurrent aphthous stomatitis:A randomised controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/11/010522
Enrollment
40
Registered
2017-11-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Recurrent minor aphthous ulcer

Interventions

Intervention1: Montelukast 10mg: Tab. Montelukat 10mg to be taken orally one tablet every evenings for 1 month and one in alternate evenings in 2nd month. Control Intervention1: Tab B complex: Tab. B

Sponsors

Thomas K Paliekkara
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with history of minor recurrent aphthous stomatitis with 1-3 minor aphthous ulcer per outbreak and 2-5 episodes per year will be selected and each ulcer should last more than 5 days.

Exclusion criteria

Exclusion criteria: 1) Patients allergic to montelukast. 2) Subjects with any known case of systemic disorders, psychiatric disorders, with special health care needs 3) Subjects with RAS lesions along with skin, other mucosal involvements, traumatic ulcers, drug induced ulcers or RAS like lesions. 4) Pregnant and lactating mothers.

Design outcomes

Primary

MeasureTime frame
Decrease of pain due to ulcer using Visual Analogue scale(VAS),decrease in number of ulcers,decrease in number of days needed for healing of ulcers.Timepoint: 1st month, 2nd month and 6th month after treatment

Secondary

MeasureTime frame
Will check the frequency of recurrence of fresh minor recurrent aphthous ulcersTimepoint: 1 year

Countries

India

Contacts

Public ContactProf Dr Auswaf Ahsan

KMCT DENTAL COLLEGE

auswaf@yahoo.com9895080789

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026